Background: The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy and other parameters. Itraconazole is a world-wide tolerated antifungal but only a few studies have focused on its assessment in the treatment of IH. Objective: This study aim was to investigate the newly proposed antifungal drug ICZ and characterize different aspects of its usage as antiangiogenic drug. Methods: This is an interventional clinical trial to assess the efficacy of ICZ versus propranolol in the treatment of infantile hemangioma with studying the change in serum Ang2. A total of 36 pediatric patients were divided into two equal groups first treated with oral itraconazole, second treated by oral propranolol. Results: Response to treatment was observed using modified IH score. In itraconazole treated infants, good response was observed in 44.4 % of the patients. This was slightly higher than the propranolol group which showed 22.2% with good response. We observed a decrease in serum ang2 level after usage of ICZ & propranolol and the change in serum angiopoietin2 level before and after treatment in each group was statistically significant (p<0.001). Conclusion: Oral itraconazole can be an equivalent option for oral propranolol while safer and shorter treatment periods.